Protara Therapeutics, Inc.

NasdaqGM:TARA Stock Report

Market Cap: US$123.1m

Protara Therapeutics Management

Management criteria checks 3/4

Protara Therapeutics' CEO is Jesse Shefferman, appointed in Jan 2020, has a tenure of 5.33 years. total yearly compensation is $1.79M, comprised of 35.3% salary and 64.7% bonuses, including company stock and options. directly owns 2.33% of the company’s shares, worth $2.87M. The average tenure of the management team and the board of directors is 3.1 years and 5.3 years respectively.

Key information

Jesse Shefferman

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage35.29%
CEO tenure5.3yrs
CEO ownership2.3%
Management average tenure3.1yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Mar 28

We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely

Mar 07
We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 10

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Nov 22
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

Aug 08
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Dec 16
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Apr 22
We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

The Prognosis For Protara Therapeutics

Oct 13

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Mar 21
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

CEO Compensation Analysis

How has Jesse Shefferman's remuneration changed compared to Protara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$45m

Dec 31 2024US$2mUS$632k

-US$45m

Sep 30 2024n/an/a

-US$42m

Jun 30 2024n/an/a

-US$41m

Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$2mUS$608k

-US$40m

Sep 30 2023n/an/a

-US$69m

Jun 30 2023n/an/a

-US$67m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$588k

-US$66m

Sep 30 2022n/an/a

-US$37m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$45m

Dec 31 2021US$4mUS$570k

-US$47m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$43m

Mar 31 2021n/an/a

-US$37m

Dec 31 2020US$8mUS$507k

-US$34m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$379kUS$344k

-US$8m

Sep 30 2019n/an/a

-US$7m

Dec 31 2018US$301kUS$268k

-US$4m

Compensation vs Market: Jesse's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD656.30K).

Compensation vs Earnings: Jesse's compensation has been consistent with company performance over the past year.

CEO

Jesse Shefferman (52 yo)

5.3yrs

Tenure

US$1,791,843

Compensation

Mr. Jesse Shefferman serves as Chief Executive Officer, President and Director of Protara Therapeutics, Inc. (Formerly known as Proteon Therapeutics Inc.) since January 2020. He Co-founded Protara Therapeu...

Leadership Team

NamePositionTenureCompensationOwnership
Jesse Shefferman
Co-founder5.3yrsUS$1.79m2.33%
$ 2.9m
Jacqueline Zummo
Co-Founder & Chief Scientific Operations Officer4.3yrsUS$1.21m0.14%
$ 175.4k
Patrick Fabbio
Chief Financial Officer2.3yrsUS$1.02m0.012%
$ 14.3k
Hannah Fry
VP, Principal Accounting Officer & Controller2.8yrsno data0.054%
$ 67.0k
Justine O'Malley
Senior Vice President of Investor Relations & Corporate Affairs3.3yrsno datano data
Mary Grendell
General Counsel & Corporate Secretary3.3yrsno datano data
Shane Williams
Chief People Officerless than a yearno datano data
Leonardo Nicacio
Chief Medical Officerless than a yearno data0.0059%
$ 7.3k

3.1yrs

Average Tenure

46yo

Average Age

Experienced Management: TARA's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jesse Shefferman
Co-founder5.3yrsUS$1.79m2.33%
$ 2.9m
Luke Beshar
Independent Chairman of the Board6.6yrsUS$192.10k0.082%
$ 100.4k
Richard Levy
Independent Director5.3yrsUS$112.47k0%
$ 0
Gregory Sargen
Independent Director5.3yrsUS$75.60k0%
$ 0
Michael Solomon
Independent Director5.3yrsUS$72.72k0%
$ 0
Roger Garceau
Independent Director5.3yrsUS$91.60k0%
$ 0
Cynthia Smith
Independent Director4.3yrsUS$72.60k0%
$ 0
Barry Flannelly
Independent Director4.8yrsUS$66.60k0%
$ 0
Edna Huang
Independent Director3.9yrsUS$85.60k0%
$ 0

5.3yrs

Average Tenure

58yo

Average Age

Experienced Board: TARA's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/17 21:42
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Protara Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Leland GershellOppenheimer & Co. Inc.